HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ALLK, CRON, FNKO Investors: 13-DAY DEADLINE ALERT, Investors with Losses Should Contact Firm
Allakos Inc. (ALLK)
Last allakos inc. earnings: 11/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.allakos.com/investor-relations
Company Research
Source: GlobeNewswire
SAN FRANCISCO, April 28, 2020 (GLOBE NEWSWIRE) -- Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases, including the upcoming May 11, 2020 lead plaintiff application deadline, can be found at the links provided. ALLK Investors Click Here. CRON Investors Click Here.FNKO Investors Click Here. Allakos (ALLK) Securities Class Action: Class Period: Aug. 5, 2019 - Dec. 17, 2019Lead Plaintiff Deadline: May 11, 2020Sign Up: www.hbsslaw.com/investor-fraud/ALLKContact An Attorney Now: ALLK@hbsslaw.com | 844-916-0895 The complaint alleges Defendants misled investors about the Company’s Phase 2 clinical trial (the “ENIGMA Trial”) for its flagship AK002 drug intended to treat patients with certain stomach diseases. Specifically, Defendants misrepresented and concealed that: (1) the ENIGMA Trial was poorly designed and not well-controlled; (2) A
Show less
Read more
Impact Snapshot
Event Time:
ALLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLK alerts
High impacting Allakos Inc. news events
Weekly update
A roundup of the hottest topics
ALLK
News
- Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy VolunteersGlobeNewswire
- Allakos Inc. (NASDAQ: ALLK) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $3.00 price target on the stock.MarketBeat
- AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial [Yahoo! Finance]Yahoo! Finance
- Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Allakos Provides Business Update and Reports Second Quarter 2024 Financial ResultsGlobeNewswire
ALLK
Earnings
- 5/9/24 - Miss
ALLK
Sec Filings
- 10/10/24 - Form 8-K
- 10/10/24 - Form 8-K
- 9/12/24 - Form 4
- ALLK's page on the SEC website